中生制药(01177.HK)抗肿瘤药获海外III期临床阳性结果
中生制药(01177.HK)公布,集团自主研发的抗肿瘤药「盐酸安罗替尼胶囊」(商品名:福可维),用於治疗实体瘤患者III期临床试验结果在2021美国临床肿瘤学会年会上获口头报告,成为中国首个在实体肿瘤领域获得海外注册III期临床研究阳性结果的创新药。
安罗替尼在该年会上首次披露多种晚期软组织肉瘤的APROMISS III期临床试验结果,数据显示,与目前在美国用於治疗软组织肉瘤的药物达卡巴秦对照组相比,安罗替尼在晚期滑膜肉瘤患者的治疗中有更好的疾病控制和更高的无进展生存期。而安罗替尼已在中国获批准用於治疗晚期非小细胞肺癌、软组织肉瘤、小细胞肺癌、甲状腺髓样癌四大适应症。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.